Sequoia is the second largest shareholder.
Editor’s note: This article is from WeChat public account “Financial Graffiti” (ID: caijingtuya ), author Pang Shifan, edit tuya.
According to the company’s intelligence expert “Financial Graffiti” news, Shanghai Gusen Pharmaceutical Co., Ltd. won a new round of financing, this round was invested by Sequoia Capital China, the specific amount was not disclosed.
In the case of shareholders of Gusen Pharmaceutical, Sequoia Capital subscribed RMB 1,076,355 in the name of the investment partnership of Sequoia Zhisheng, Ningbo Meishan Bonded Port Area, with a shareholding ratio of 12.5%, which is the company’s second Major shareholder.
Gusen Pharmaceutical was established in 2017, with high-end preparations, especially the new generation of high-efficiency inhaler-inhalation aerosol technology products, combined with research and development platforms such as Peking University, Fudan University, Shanghai Institute of Chinese Medicine, and Shenyang Pharmaceutical University. Resources for the production of pharmaceuticals, the creation of the “production, study and research” ecological chain.
The company’s R&D team and R&D/industrialization base are in the leading position in the industry. The high-end preparations, drug delivery technologies, and aerosol technology and products for R&D are far ahead in the country, and they are the best inhalation aerosols. It has applied for a series of patents and occupied the commanding heights in this field. It is the only enterprise in the country that has obtained the “major special project” of inhaling soft fog, and has upgraded China’s high-end preparations to the world’s leading level.
The company currently has R&D centers in Shanghai, Nanchang and Ningbo. It has also received financial support from the provincial government in the R&D center in Nanchang.
On October 10 this year, the official website of the Jiangxi Provincial People’s Government announced the announcement of investing in Gusen Medicine. The provincial guiding fund invested RMB 30 million, the provincial talent fund invested RMB 0.2 billion, and incited social capital of RMB 0.5 billion, totaling 100 million yuan.Yuan’s Jiangxi Provincial Development and Upgrading Guidance Fund invested exclusively in Gusen Medicine to support its R&D and production base projects in the Nanchang Economic Development Zone.
This investment will help Gusen Pharmaceutical to develop the world’s first soft mist imitation product for respiratory diseases. At the beginning of 2018, Gusen Pharmaceutical invested a total of 300 million yuan in the construction of high-end pharmaceutical research and development center in Nanchang Economic Development Zone. Production base projects, if the smooth production of the soft aerosol imitation products will reduce the pressure on patients for a lot of money.
At present, the company has three inhaled soft mist preparations selected into the national thirteenth five-year “major new drug creation” technology major project, inhalation soft aerosol research and development and industrialization is at the forefront of domestic and foreign counterparts. In terms of specific products, the company has a wealth of research and development products, there are 5 inhaled soft aerosol first sample drugs, two of which are in the pilot stage. In addition, there are many backup products: there are 10 inhaled soft aerosols for 505(b)2 new drugs (domestic 2 new drugs), and these products are expected to have a global market of about 20 billion US dollars.